Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview

Cadrenal Therapeutics

07/08/2026 16:43

Cadrenal Therapeutics Inc CVKD.OQ CVKD.O is expected to  show no change in quarterly revenue when it reports  results on August 10 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Cadrenal Therapeutics Inc is for a loss of $1.42 per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Cadrenal Therapeutics Inc is $13.00, about 595.2% above its last closing price of $1.87
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-1.63
-1.62
-1.04
Beat
35.8
Dec. 31 2026
-1.12
-1.16
-1.43
Missed
-22.7
Sep. 30 2025
-1.45
-1.53
-1.31
Beat
14.2​
Jun. 30 2025
-1.77
-1.60
-1.87
Missed
-17.1
​​Mar. 31 2025
-1.13
-1.64
-2.09
Missed
-27.4
Dec. 31 2024
-1.41
-1.71
-2.74
Missed
-59.9​
Sep. 30 2024
-1.94
-1.93
-2.18
Missed
-13.1
Jun. 30 2024
-1.80
-1.27
-2.25
Missed
-76.5
This summary was machine generated August 7 at 15:43 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)